Kanyilmaz Gul, Aktan Meryem, Koc Mehmet, Demir Hikmettin, Demir Lütfi Saltuk
Department of Radiation Oncology, Necmettin Erbakan University Meram Medicine School, Akyokus Mevkii, 42090, Konya, Turkey.
Department of Public Health and Biostatistics, Necmettin Erbakan University Meram Medicine School, Konya, Turkey.
Radiol Med. 2017 Jun;122(6):405-411. doi: 10.1007/s11547-017-0747-5. Epub 2017 Mar 3.
To evaluate the incidental dose to the internal mammary chain (IMC) in patients treated with three-dimensional conformal radiotherapy, to estimate the predictors affecting the magnitude of IMC receiving dose and to determine the predictive role of clinical parameters on survival.
Between 2009 and 2015, 348 patients undergoing RT for breast cancer were retrospectively analyzed. All patients underwent our department's routine procedure for breast cancer. The internal mammary lymph nodes were contoured according to Radiation Therapy Oncology Group (RTOG) concensus. Based on each patient's dose-volume histograms, the mean doses (D ) to internal mammary gland were analyzed. Overall survival and disease-free survival were also evaluated.
The median follow-up time was 38 (range 3-80) months. The D to IMC was 32.8 Gy and the dose delivered to IMC showed a greater coverage in modified radical mastectomy (MRM) group compared with breast conserving surgery (34.6 vs 26.7 Gy). The T-stage of tumor and the N-stage of tumor affected the incidental dose to IMC. The tumor size, the number of involved lymph nodes, the percentage of involved lymph nodes, hormonal status, advanced T-stage and advanced N-stage were the prognostic factors that affect survival.
The IMC received meaningful incidental irradiation dose when treated with two opposite tangential fields and ipsilateral supraclavicular fossa with a single anterior field. The real effect of incidental dose on survival and the hypothesis about the benefit of incidental irradiation of IMC should be examined in clinical studies.
评估接受三维适形放疗的患者内乳链(IMC)的附带剂量,估计影响IMC接受剂量大小的预测因素,并确定临床参数对生存的预测作用。
回顾性分析2009年至2015年间348例接受乳腺癌放疗的患者。所有患者均接受了我科乳腺癌的常规治疗。根据放射治疗肿瘤学组(RTOG)共识勾勒出内乳淋巴结。根据每位患者的剂量体积直方图,分析内乳的平均剂量(D)。还评估了总生存期和无病生存期。
中位随访时间为38(范围3 - 80)个月。IMC的D为32.8 Gy,与保乳手术相比,改良根治术(MRM)组中IMC接受的剂量覆盖范围更大(34.6 vs 26.7 Gy)。肿瘤的T分期和N分期影响IMC的附带剂量。肿瘤大小、受累淋巴结数量、受累淋巴结百分比、激素状态、晚期T分期和晚期N分期是影响生存的预后因素。
当用两个相对切线野和一个同侧锁骨上窝单前野进行治疗时,IMC接受了有意义的附带照射剂量。附带剂量对生存的实际影响以及关于IMC附带照射益处的假设应在临床研究中进行检验。